Odonate Therapeutics Stock Forecast, Price & News

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ODT stock has decreased by 36.3% and is now trading at $16.51.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Odonate Therapeutics.

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Odonate Therapeutics.

Odonate Therapeutics, Inc. (NASDAQ:ODT) released its quarterly earnings results on Thursday, July, 30th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by $0.11.
View Odonate Therapeutics' earnings history.

2 Wall Street analysts have issued 1 year price objectives for Odonate Therapeutics' shares. Their forecasts range from $26.00 to $50.00. On average, they anticipate Odonate Therapeutics' stock price to reach $38.00 in the next year. This suggests a possible upside of 130.2% from the stock's current price.
View analysts' price targets for Odonate Therapeutics.

Odonate Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 2,060,000 shares, an increase of 32.9% from the August 31st total of 1,550,000 shares. Based on an average trading volume of 377,300 shares, the short-interest ratio is presently 5.5 days. Approximately 6.9% of the shares of the company are sold short.
View Odonate Therapeutics' Short Interest.

Some companies that are related to Odonate Therapeutics include Corcept Therapeutics (CORT), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), Amarin (AMRN), uniQure (QURE), Zymeworks (ZYME), IGM Biosciences (IGMS), Akcea Therapeutics (AKCA), Viela Bio (VIE), Intra-Cellular Therapies (ITCI), Prestige Consumer Healthcare (PBH), Cryoport (CYRX), Kura Oncology (KURA), Revance Therapeutics (RVNC) and Zentalis Pharmaceuticals (ZNTL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), The Boeing (BA), Bausch Health Companies (BHC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Athenex (ATNX), BioCryst Pharmaceuticals (BCRX) and Crispr Therapeutics (CRSP).

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Odonate Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.53%). Company insiders that own Odonate Therapeutics stock include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang.
View institutional ownership trends for Odonate Therapeutics.

ODT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought Odonate Therapeutics stock in the last two years include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang.
View insider buying and selling activity for Odonate Therapeutics.

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ODT stock can currently be purchased for approximately $16.51.

Odonate Therapeutics has a market capitalization of $530.42 million. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 134 workers across the globe.

The official website for Odonate Therapeutics is www.odonate.com.

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]